24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
LEUPOLIEVA DEPOT 11.25 MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | LEUPOLIEVA DEPOT 11.25 MG |
|---|---|
| Composition | Leuprolide Acetate Depot for Injection 11.25 mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | 1 Vial & 1 x 2mL Ampoule |
| Country of Origin | India |
LEUPOLIEVA DEPOT 11.25 MG (Leuprolide Acetate Depot for Injection 11.25 mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
LEUPOLIEVA DEPOT (Leuprolide Acetate Depot for Injection 11.25 mg) is a prescription hormonal medicine containing Leuprolide Acetate 11.25 mg in a long-acting depot formulation. Leuprolide is a Gonadotropin-Releasing Hormone (GnRH) agonist used in the management of hormone-dependent conditions and certain cancers.
Leuprolide initially stimulates the pituitary gland to release gonadotropins. With continued administration, it suppresses the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), resulting in a significant reduction in testosterone levels in males and estrogen levels in females.
LEUPOLIEVA DEPOT 11.25 MG is commonly used in the management of advanced prostate cancer and may also be prescribed for certain hormone-dependent conditions such as endometriosis and uterine fibroids, depending on the approved indication and treatment plan.
The depot formulation is designed to provide sustained release of Leuprolide Acetate over an extended period, reducing the need for frequent administration.
The medicine is administered by a qualified healthcare professional according to the prescribed treatment schedule.
LEUPOLIEVA DEPOT is commonly used for:
Patients receiving Leuprolide therapy require regular monitoring of treatment response, hormone levels, and relevant clinical parameters.
LEUPOLIEVA DEPOT (Leuprolide Acetate Depot for Injection 11.25 mg) is primarily used in conditions where suppression of sex hormones is clinically beneficial.
Leuprolide is widely used as androgen deprivation therapy (ADT) for advanced prostate cancer. It reduces testosterone production, which can help slow the growth of hormone-sensitive prostate cancer cells.
Leuprolide may be used to reduce estrogen stimulation and help manage pain and other symptoms associated with endometriosis.
It may be prescribed in selected patients to temporarily reduce estrogen levels and decrease the size of uterine fibroids.
The medicine can be used when temporary suppression of gonadal hormone production is clinically required.
For prostate cancer, Leuprolide may be used alongside other medicines depending on the patient's treatment plan.
Leuprolide belongs to the class of medicines known as GnRH Agonists.
LEUPOLIEVA DEPOT works by:
In prostate cancer, lowering testosterone can help slow the growth of androgen-dependent cancer cells.
Like all medicines, LEUPOLIEVA DEPOT 11.25 MG may cause side effects. Their severity and frequency vary among individuals.
Sudden feelings of warmth and sweating are commonly reported.
Pain, redness, swelling, or discomfort may occur at the injection site.
Some patients may experience weakness or tiredness.
Headache may occur during treatment.
Reduced sexual desire may occur due to hormonal suppression.
Men receiving androgen deprivation therapy may experience difficulty achieving or maintaining an erection.
Changes in mood or emotional well-being may occur.
Long-term hormone suppression may contribute to reduced bone mineral density.
Changes in body weight or body composition may occur during prolonged treatment.
Seek immediate medical attention if you experience:
Patients should promptly inform their healthcare provider about severe or unusual symptoms.
The dosage and administration schedule of LEUPOLIEVA DEPOT (Leuprolide Acetate Depot 11.25 mg) should be determined by a qualified healthcare professional according to the specific indication.
The 11.25 mg depot formulation is designed for extended-duration treatment, but the exact administration interval depends on the product formulation and approved prescribing information.
The treatment schedule differs depending on whether the medicine is being used for prostate cancer, endometriosis, or another approved indication.
Clinical response and hormone suppression may influence ongoing treatment decisions.
Individual health status may affect treatment planning.
Other hormonal or anticancer medicines may be used alongside Leuprolide.
Before starting treatment, inform your doctor if you have:
Depending on the indication, patients may require:
Patients should inform their healthcare professional about all prescription medicines, supplements, vitamins, and herbal products they are taking.
During the initial phase of Leuprolide treatment, testosterone levels can temporarily rise before they fall. This is known as a tumor flare.
In some patients with advanced prostate cancer, this temporary hormonal increase can worsen symptoms such as:
Doctors may prescribe an additional medicine to reduce the risk or impact of tumor flare when clinically appropriate.
It is commonly used for advanced prostate cancer and may also be prescribed for conditions such as endometriosis and uterine fibroids, depending on the approved indication.
Leuprolide Acetate is a GnRH agonist that suppresses the production of sex hormones when administered continuously.
No. Leuprolide is a hormonal therapy, not a traditional cytotoxic chemotherapy medicine.
It reduces testosterone production, thereby reducing hormonal stimulation of prostate cancer cells.
Tumor flare is a temporary worsening of certain prostate cancer symptoms caused by the initial increase in testosterone after starting GnRH agonist therapy.
Yes. Long-term hormone suppression can reduce bone mineral density, so bone health may need to be monitored.
Yes. Hot flashes are a common effect of hormonal suppression.
Yes. The depot injection should be administered by a qualified healthcare professional according to the prescribed treatment schedule.